LIFE bioCEEd

14/04/2026

LIFE BioCEEd at BioVaria 2026 in Munich

We are excited to announce that LIFE BioCEEd Medical Investments will be attending BioVaria 2026, taking place on 27–28 April in Munich, Germany.

BioVaria is one of Europe’s leading life sciences events, bringing together top innovators, startups, and investors. It offers a unique platform to showcase breakthrough technologies, explore early-stage opportunities, and build meaningful partnerships across the biotech and pharma ecosystem.

We are looking forward to connecting with inspiring innovators, discovering new technologies, and exploring potential collaborations.

Representing LIFE BioCEEd at the event will be Katarína Orsághová, Ph.D. Katarína holds a PhD from Charles University in collaboration with IOCB Prague. Her research focused on proteolytic enzymes and contributed to the development of novel inhibitors. She combines expertise in biochemistry, molecular biology, and crystallography with a strong interest in translating scientific discoveries into real-world biomedical applications.

At LIFE BioCEEd, she focuses on evaluating innovative biotech ventures in proteomics, enzyme engineering, and molecular medicine, helping identify projects with strong scientific and clinical potential.

If you will be there, feel free to reach out. Katarína Orsághová, Ph. D.

We look forward to meeting you in Munich!

15/10/2026

LIFE bioCEEd Featured in Wired Czech Republic – Only Innovation Gives a Nation Wealth and Independence

Our co-founder Michal Zahradníček spoke with Wired Czech Republic about why excellent Czech and European science so rarely turns into new technologies and globally successful companies, and what needs to change for research results to make their way from the laboratory into practice.

23/09/2026

LIFE bioCEEd Featured on The Forbes Show – Investing Where Innovation Can Ease Suffering

Our co-founder Michal Zahradníček was a guest on the latest episode of The Forbes Show, a podcast by Forbes Czech Republic. He spoke about his path into biotechnology, regenerative medicine, artificial organs, and also about investments that did not work out.

07/07/2026

LIFE bioCEEd Invests into Potentially First-in-Class microRNA-Targeting Therapy for ALS from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

LIFE bioCEEd invests into a potentially first-in-class therapeutic platform for Amyotrophic Lateral Sclerosis (ALS) from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy, one of Europe's foremost academic medical centres. The platform, developed in the Neural Stem Cell Laboratory of Professor Stefania Corti, is based on a novel anti-miR morpholino antisense oligonucleotide (ASO) that targets the microRNA-129-1 (miR-129-1) pathway, with the aim of achieving genuine disease modification across a broad population of ALS patients, regardless of their genetic background. The agreement was signed on 1 July 2026 and expands LIFE bioCEEd's growing portfolio of innovative biomedical programmes across Europe.